Skip to content

Effect of Pilates Application on Abdominal Muscle Function, Core Stability, Musculoskeletal Pain, Quality of Life, Anxiety and Depression in Parkinson's Patients

The Effect of Pilates Application on Abdominal Muscle Function, Core Stability, Musculoskeletal Pain, Quality of Life, Anxiety and Depression in Parkinson's Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04619784
Enrollment
20
Registered
2020-11-06
Start date
2018-04-16
Completion date
2021-12-31
Last updated
2020-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle Function, Parkinson Disease, Pilates

Brief summary

In this study, it is aimed to investigate the effect of Pilates application on abdominal muscle function, core stability, musculoskeletal pain, quality of life, anxiety and depression in Parkinson's Patients.

Detailed description

Objective: In this study, it is aimed to investigate the effect of Pilates application on abdominal muscle function, core stability, musculoskeletal pain, quality of life, anxiety and depression in Parkinson's Patients. Method: The study included 15 Idiopathic Parkinson's Patients over 18 years of age, under stage 3 according to the Hoehn-Yahr clinical staging. Patients were divided into intervention and control groups. Pilates training was performed for 6 weeks, twice a week and 60 minutes per session in intervention group. Demographic features will be questioned and recorded in the data recording form through mutual interview in patients who meet the inclusion criteria; evaluations will be made regarding muscle thickness and pain. All patients will be evaluated before treatment, after treatment, at the 3rd and 6th months.

Interventions

OTHERPilates Exercises

Patients will receive 12 sessions of pilates.

OTHERcontrol

Their routine medical treatments were continued

Sponsors

Dokuz Eylul University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosed with Idiopathic Parkinson's Disease * Must be older 18 years old * Must have 24 and above score on Mini Mental Test * Must be the third or lower stage according to the Hoehn-Yahr staging * Must have stable clinical status

Exclusion criteria

* Musculoskeletal or cognitive impairment at a level affecting evaluation and treatment * Other neurological disease

Design outcomes

Primary

MeasureTime frameDescription
Muscle FunctionPatients will be evaluated before treatment, 1 week after treatment, at the 3rd and 6th months after treatmentMuscle thickness measurement will be used to evaluate the function of transversus. Ultrasonography with a linear transducer (MHz) will use to measure the Transversus Abdominis thickness both at rest and during the abdominal drawing-in maneuver (ADIM). During ADIM, participants will be asked to abdominal hollowing which will be a gentle voluntary contraction of abdominal wall. All images are obtained at the end of expiration not to allow the effect of respiration on muscle thickness. Three measures are recorded in the both condition. The average values of measures are used in the data analysis.

Secondary

MeasureTime frameDescription
Musculoskeletal PainPatients will be evaluated before treatment, 1 week after treatment, at the 3rd and 6th months after treatmentMusculoskeletal pain will be evaluated with The Nordic Musculoskeletal Questionnaire. Questionnaire includes 27 items exploring the presence of musculoskeletal symptoms during a 12-month period covering in nine different parts of the body (i.e. neck, shoulders, elbows, wrists/hands, upper back, lower back, hips/tights, knees, ankles/feet) \[21\]. It also has items pertaining to severity grades, determined according to functional status and the presence of musculoskeletal symptoms during the last seven days. All answers are given according to a dichotomous 'yes/no' response.The Turkish version of the NMQ has appropriate psychometric properties, including good test-retest reliability, internal consistency and construct validity.
Quality of LifePatients will be evaluated before treatment, 1 week after treatment, at the 3rd and 6th months after treatmentQuality of Life will be evaluated with 8-Item Parkinson's Disease Questionnaire / PDQ-8.The PDQ-8 is a brief form of the PDQ-39. One question from each of the eight domains on the PDQ-39 which are activities of daily living, bodily discomfort, cognition, communication, emotional well-being, mobility, social support, and stigma was chosen based on the strength of its correlation with the total domain score. Each question was scored from 0-4 points, and the scores were summed. The summed score was then divided by total possible score, and given as a percentage score out of 100.
Core stabilityPatients will be evaluated before treatment, 1 week after treatment, at the 3rd and 6th months after treatmentCore endurance and core power are the specific components of core stability and will be evaluated separately.
Pain intensityPatients will be evaluated before treatment, 1 week after treatment, at the 3rd and 6th months after treatmentPain intensity will be evaluated with Visual Analog Scale. 10 cm long horizontal or vertical, numbered 1-10 forms are used.0 means no pain, 10 means unbearable pain.
DepressionPatients will be evaluated before treatment, 1 week after treatment, at the 3rd and 6th months after treatment.Depression will be evaluated with Beck Depression Inventory. It is a 21-item scale. The items contain sentences of four degrees that progress from less to more, which the participant will evaluate himself. The scale can be scored between 0 and 63. The high total score indicates the severity of the depression.
AnxietyPatients will be evaluated before treatment, 1 week after treatment, at the 3rd and 6th months after treatmentAnxiety will be evaluated with Beck Anxiety Inventory. It is a 21-item questionnaire that includes 4-point Likert-type options with a score of 0-3 and measures the level of anxiety. The higher the total score indicates the severity of anxiety.

Countries

Turkey (Türkiye)

Contacts

Primary ContactEvrim GOZ
Evrim.goz@deu.edu.tr02324124900

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026